September 3, 2014 — GE Healthcare has announced U.S. Food and Drug Administration (FDA) approval of SenoClaire, GE’s new breast tomosynthesis solution designed with three-dimensional imaging technology. In collaboration with Massachusetts General Hospital, GE developed SenoClaire technology that uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a “step-and-shoot” method, removing the potential motion from the tube, helping to reduce blur and increase image sharpness.
A key challenge when performing screening mammography is keeping the radiation levels as low as possible. With GE’s SenoClaire, there is no increase in radiation dose from a 2-D standard mammogram to a 3-D view.
SenoClaire offers a complete solution by helping to improve overall workflow. SenoClaire is compatible with Centricity picture archiving and communications systems (PACS) with Universal Viewer and supports the digital imaging and communications in medicine (DICOM) standard that can be read by capable PACS vendors. When SenoClaire is combined with GE Healthcare’s Centricity PACS and Centricity Clinical Archive solution, clinicians have access to the patient’s longitudinal record, providing data that helps to enable better patient care.
Currently, GE Healthcare has 180 units installed in Europe, Australia, Latin America, Southeast Asia and the Middle East.
For more information: www.gehealthcare.com
March 31, 2026 
